These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 34504023)

  • 1. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
    Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
    Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
    Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
    Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
    Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
    Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Hao Q; Kanda M; Tani Y
    BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
    van Lierop ZY; Wieske L; Koel-Simmelink MJ; Chatterjee M; Dekker I; Leurs CE; Willemse EA; Moraal B; Barkhof F; Eftimov F; Uitdehaag BM; Killestein J; Teunissen CE
    Mult Scler; 2022 Jan; 28(1):102-110. PubMed ID: 33890520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
    Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
    CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
    J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of neurofilament light chain in natalizumab therapy for different phases of multiple sclerosis: A systematic review and meta-analysis.
    Liu N; Sun M; Zhang W; Sun J; Gong P; Wang H; Wang M
    J Clin Neurosci; 2022 Jul; 101():198-203. PubMed ID: 35617924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
    Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
    Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
    van Lierop ZY; Noteboom S; Steenwijk MD; van Dam M; Toorop AA; van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Teunissen CE; Killestein J
    Mult Scler; 2022 Dec; 28(14):2231-2242. PubMed ID: 36062492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
    Fissolo N; Pignolet B; Rio J; Vermersch P; Ruet A; deSèze J; Labauge P; Vukusic S; Papeix C; Martinez-Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Bourre B; Defer G; Montalban X; Brassat D; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33903203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study 'TOPICS Greece'.
    Efthimios D; Georgios K; Antonia A; Rania G; Maria-Eleutheria E;
    Clin Drug Investig; 2021 Oct; 41(10):865-874. PubMed ID: 34427893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
    Wiendl H; Butzkueven H; Kappos L; Trojano M; Pellegrini F; Paes D; Zhang A; Belachew S;
    PLoS One; 2016; 11(1):e0144834. PubMed ID: 26771747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.